Posts

Posted on

CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

LARGO, Fla.–(BUSINESS WIRE)–CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the second quarter 2026 after the market close on Wednesday, July 29, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results.

To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode.

This conference call will also be webcast and can be accessed from the “Investors” section of CONMED’s website: https://www.conmed.com/en/investor-relations. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

About CONMED Corporation

CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, and thoracic surgery. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and associated conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company’s Annual Report on Form 10-K for the full year ended December 31, 2025, listed under the heading Forward-Looking Statements in the Company’s most recently filed Form 10-Q and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.

CONMED Corporation

Dalton Henry

Investor Relations Analyst

[email protected]

KEYWORDS: Florida United States North America

INDUSTRY KEYWORDS: Health Technology Health Surgery Medical Devices

MEDIA:

Logo
Logo
Posted on

Sixth Street Specialty Lending, Inc. Schedules Earnings Release and Conference Call to Discuss Its Second Quarter Ended June 30, 2026 Financial Results

Sixth Street Specialty Lending, Inc. Schedules Earnings Release and Conference Call to Discuss Its Second Quarter Ended June 30, 2026 Financial Results

NEW YORK–(BUSINESS WIRE)–Sixth Street Specialty Lending, Inc. (NYSE: TSLX) (“TSLX” or “the Company”) announced today that it will release its financial results for the second quarter ended June 30, 2026 on Tuesday, August 4, 2026, after the market closes. TSLX invites all interested persons to its webcast / conference call on Wednesday, August 5, 2026 at 8:30 a.m. Eastern Time to discuss these results.

Conference Call Information:

The conference call will be broadcast live in listen-only mode at 8:30 a.m. Eastern Time on the Investor Resources section of TSLX’s website at https://sixthstreetspecialtylending.gcs-web.com/events-and-presentations. Please visit the website to test your connection before the webcast. A recorded version will be available under the same link following the conclusion of the conference call.

Research analysts who wish to participate in the conference call must first register at https://register-conf.media-server.com/register/BIb094b698d91c489080310428d3254a9e. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.

About Sixth Street Specialty Lending
Sixth Street Specialty Lending is a specialty finance company focused on lending to middle-market companies. The Company seeks to generate current income primarily in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine loans and investments in corporate bonds and equity securities. The Company has elected to be regulated as a business development company, or a BDC, under the Investment Company Act of 1940 and the rules and regulations promulgated thereunder. The Company is externally managed by Sixth Street Specialty Lending Advisers, LLC, an affiliate of Sixth Street and a Securities and Exchange Commission (“SEC”) registered investment adviser. The Company leverages the deep investment, sector, and operating resources of Sixth Street, a global investment firm with over $130 billion in assets under management and committed capital. For more information, visit the Company’s website at https://sixthstreetspecialtylending.com.

About Sixth Street
Sixth Street is a global investment firm with over $130 billion in assets under management and committed capital. The firm uses its long-term flexible capital, data-enabled capabilities, and One Team culture to develop themes and offer solutions to companies across all stages of growth. Founded in 2009, Sixth Street has more than 750 team members including over 300 investment professionals around the world. For more information, visit https://sixthstreet.com or follow Sixth Street on LinkedIn.

Forward-Looking Statements
Statements included herein may constitute “forward-looking statements,” which relate to future events or the Company’s future performance or financial condition. These statements are not guarantees of future performance, conditions or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in the Company’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update any such forward-looking statements.

Investors:

Cami Senatore, 469-621-2033
Sixth Street Specialty Lending
[email protected]

Media:

Patrick Clifford, 617-793-2004
Sixth Street
[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Data Analytics Professional Services Finance

MEDIA:

Posted on

Ryerson to Host Earnings Call on Thursday, July 30th to Discuss Second Quarter 2026 Results

PR Newswire

CHICAGO, July 2, 2026 /PRNewswire/ — Ryerson Holding Corporation (NYSE: RYZ), a leading value-added processor and distributor of industrial metals, today announces that it will host a conference call to discuss its second quarter 2026 financial results for the period ended June 30th, 2026 on Thursday, July 30th at 10 a.m. Eastern Time. The live online broadcast will be available on the Company’s Investor Relations website, ir.ryerson.com. Ryerson will report earnings after the market closes on Wednesday, July 29th. 

Ryerson Logo

Ryerson Holding Corporation’s Second Quarter

2026 Earnings Call Details:


DATE:

Thursday, July 30, 2026


TIME:

10:00 a.m. ET / 9:00 a.m. CT


DIAL-IN:

800-330-6710 (U.S. & Canada) / 646-769-9200 (International)


CONFERENCE ID: 

9444043

An online replay of the call will be posted on the investor relations website, ir.ryerson.com, and remain available for 90 days.

Ryerson is a leading value-added processor and distributor of industrial metals, with operations in the United States, Canada, Mexico, and China. Founded in 1842, Ryerson has around 6,400 employees in approximately 150 locations. Visit Ryerson at www.ryerson.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ryerson-to-host-earnings-call-on-thursday-july-30th-to-discuss-second-quarter-2026-results-302817208.html

SOURCE Ryerson Holding Corporation

Posted on

STANDEX ACQUIRES REMAINING INTEREST IN NARAYAN POWERTECH

PR Newswire

SALEM, N.H., July 2, 2026 /PRNewswire/ — Standex International Corporation (NYSE:SXI) today announced that it has acquired the remaining 9.9% interest in India-based Narayan Powertech (Narayan), a leading manufacturer of low voltage and medium voltage instrument transformers, for approximately $64 million.

“We are pleased with the smooth integration of Narayan and Amran. Our internal teams are completely focused on meeting customer demand now and in the future,” said David Dunbar, President and Chief Executive Officer of Standex.

“Narayan and Standex Grid have created a stronger player in the transformer industry, with the ability to leverage a larger global footprint and portfolio breadth to create increased value for our customers,” added Chirag Shah, Managing Director of Narayan Powertech and Founder. “I am thrilled to continue the journey with other key team members as part of a global leader like Standex.”

About Standex

Standex International Corporation is a multi-industry manufacturer in four broad business segments: Electronics, Aerospace & Defense, Scientific, and Engraving & Hydraulics with operations in the United States, Europe, Canada, Japan, Singapore, Mexico, Turkey, India, and China. For additional information, visit the Company’s website at https://standex.com/.

About Narayan

Narayan Powertech Pvt. Ltd, designs and manufactures low voltage and medium voltage transformers for products focused on the electrical grid. For additional information, visit the Company’s related website at narayanpowertech.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/standex-acquires-remaining-interest-in-narayan-powertech-302817075.html

SOURCE Standex International Corporation

Posted on

Scholastic Corporation Announces Date for Fourth Quarter and Fiscal 2026 Earnings Release and Conference Call

PR Newswire

NEW YORK, July 2, 2026 /PRNewswire/ — Scholastic Corporation (NASDAQ: SCHL) today announced the following schedule and conference call information for its fourth quarter and fiscal year 2026 earnings announcement:

Scholastic Logo. (PRNewsFoto/Scholastic) (PRNewsFoto/SCHOLASTIC) (PRNewsFoto/SCHOLASTIC)

  • Earnings Release: Thursday, July 23, 2026, at 4:00 PM ET and posted on the Company’s investor relations website, investor.scholastic.com.

  • Conference Call: Thursday, July 23, 2026, at 4:30 PM ET hosted by Peter Warwick, President and CEO, and Haji Glover, CFO and Executive Vice President. A live webcast of the call can be accessed at https://edge.media-server.com/mmc/p/n2mcunuo. To access the conference call by phone, please go to https://register-conf.media-server.com/register/BIe4453c04814b4def819b83eaf92a8731, which will provide dial-in details. To avoid delays, we encourage participants to dial into the conference call five minutes ahead of the scheduled start time.

  • Archived Webcast and Audio Replay: The archived webcast and accompanying slides will be available on the Company’s investor relations website shortly after the completion of the live call.

About Scholastic

For more than 100 years, Scholastic Corporation (NASDAQ: SCHL) has been meeting children where they are – at school, at home and in their communities – by creating quality content and experiences, all beginning with literacy. Scholastic delivers stories, characters, and learning moments that empower all kids to become lifelong readers and learners through bestselling children’s books, literacy- and knowledge-building resources for schools including classroom magazines, and award-winning, entertaining children’s media. As the world’s largest publisher and distributor of children’s books through school-based book clubs and book fairs, classroom libraries, school and public libraries, retail, and online, and with a global reach into more than 135 countries, Scholastic encourages the personal and intellectual growth of all children, while nurturing a lifelong relationship with reading, themselves, and the world around them. Learn more at www.scholastic.com.

SCHL: Financial

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/scholastic-corporation-announces-date-for-fourth-quarter-and-fiscal-2026-earnings-release-and-conference-call-302817163.html

SOURCE Scholastic Corporation

Posted on

Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)

NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees. The inducement grants were approved by the Company’s independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of non-qualified stock options to purchase an aggregate of 58,000 shares of the Company’s common stock with a 10-year term and an exercise price of $90.21 per share. The options vest as to 25% on the first anniversary of the vesting commencement date and in equal monthly installments for the following 36 months. The inducement grants are subject to the terms and conditions of the Dianthus Therapeutics, Inc. Equity Inducement Plan, and the terms and conditions of a stock option agreement.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact

Jennifer Davis Ruff
Dianthus Therapeutics
[email protected]



Posted on

Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of inducement equity awards to three newly hired non-executive employees as a material inducement to commencing their employment with the Company.

The employees received, in the aggregate, non-qualified stock options to purchase 18,025 shares of Monte Rosa Therapeutics common stock, par value $0.0001 per share, with an exercise price per share equal to the closing price of $24.02 as reported by Nasdaq on July 1, the effective date of the grant or the “Grant Date”, which will vest 25% on the first anniversary of the Grant Date and in 36 equal monthly installments thereafter, subject to the employee’s continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 3,900 shares of Monte Rosa Therapeutics common stock, which will vest 25% on each of the first four anniversaries of the Grant Date, subject to the employee’s continued service with the Company through each applicable vesting date, or collectively, the Awards.

All of the above-described Awards were granted outside of stockholder-approved equity incentive plans and are pursuant to the Monte Rosa Therapeutics, Inc. 2026 Inducement Plan. The Awards were approved by the compensation committee of the board of directors, which is comprised solely of independent directors, as a material inducement to the employees entering into employment in accordance with Nasdaq Listing Rule 5635(c)(4).

About Monte Rosa

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
[email protected]

Media
Cory Tromblee, Scient PR
[email protected]



Posted on

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, July 02, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on July 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 951 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4).

The restricted stock units will vest in four equal annual installments, subject to the employee’s continued employment with Praxis on each vesting date.

About Praxis

Praxis Precision Medicines is a fully integrated, leading CNS precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.



Contacts:
Investor Contact:
Praxis Precision Medicines
[email protected] 
857-702-9452

Media Contact:
Dan Ferry
LifeSci Advisors
[email protected] 
617-430-7576

Posted on

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 20,200 share options and 11,850 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of July 1, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The share options have an exercise price of $60.30 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of July 1, 2026. The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee’s start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient’s continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan. The RSUs will vest as to 25% of the underlying shares on each of the first four anniversaries of the respective employee’s start date, subject to such employee’s continued service relationship with the Company. Each RSU grant is subject to the terms and conditions of the restricted share unit award agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan.


About Xenon Pharmaceuticals Inc.


Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
  
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.


Contacts:


For Investors: 
Tucker Kelly 
Chief Financial Officer 
[email protected] 

For Media:

Colleen Alabiso 
Senior Vice President, Corporate Affairs 
[email protected] 



Posted on

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an aggregate of 981,243 shares of the Company’s common stock to seven newly-hired non-executive employees under the Company’s 2026 Inducement Equity Plan (the “Inducement Plan”), effective as of June 30, 2026 (the “Effective Date”). The inducement grants were previously approved by the Compensation Committee of the Company’s Board of Directors, as a material inducement to the new employees’ entry into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of $2.03 per share, which is equal to the closing price of the Company’s common stock on the Effective Date. The options have a ten year term, with 25% vesting on the first anniversary of the Effective Date and the remaining 75% vesting in 36 equal monthly installments thereafter. The options are subject to the terms and conditions of the Inducement Plan approved by the Company’s Board of Directors in March 2026 and the terms and conditions of award agreements covering the grants.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as “c-Kit” has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named IMPROVE-PAH (IKT-001 for Measuring Pulmonary Vascular Resistance and Outcome Variables in a Phase 3 Evaluation of PAH), is actively enrolling patients.

Contacts:

Investor Relations:

Michael Moyer
LifeSci Advisors
[email protected]